Transaction · 0001882764-26-000009

Hohl Benjamin

Hohl Benjamin, CFO, reported an open-market or private sale at Enliven Therapeutics, Inc. involving 6018.000000 shares for an estimated $231545.56. Reported holdings after the transaction were 38000.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
ELVNEnliven Therapeutics, Inc.
Trade date
Oct 19, 2026
Filing date
Oct 21, 2026
View on SEC Insider profile
Estimated value-$231kShares × reported price
Shares traded6.01k$38.48 per share
Holdings after38.0kDirect
% of reported position traded13.67%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 44,018 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ELVN price since this filing

Daily closing prices, with the filing date and available return windows
ELVN · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +20.1%1w ago -2.3%1d ago -10.8%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001882764-26-000009
Common Stock
Transaction date
Oct 19, 2026
Filed Oct 21, 2026, 09:53 PM · 2d delay
Shares
6,018 sh
$38.48 per share
Estimated value
-$231k
Computed from shares × price
Holdings after
38,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Sale 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF FINANCIAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.

  2. F2

    Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and…

  3. F3

    This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provid…

  4. F4

    The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

Original filing · 0001882764-26-000009
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ELVN